In vivo modulation of cervicovaginal drug transporters and tissue distribution by film-released tenofovir and darunavir for topical prevention of HIV-1

Karolin Hijazi* (Corresponding Author), Francesco Iannelli, Anna Maria Cuppone, Delphine Desjardins, Anna Caldwell, Nathalie Dereuddre-Bosquet, Carlo Scala, Kieron A Smith, Indrani Mukhopadya, Bruce Frank, Garry Gwozdz, Francesco Santoro, Roger Le Grand, Gianni Pozzi, Charles G Kelly

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Clinical trials have demonstrated partial protection against HIV-1 infection by vaginal microbicide formulations based on antiretroviral (ARV) drugs. Improved formulations that will maintain sustained drug concentrations at viral target sites in the cervicovaginal mucosa are needed. We have previously demonstrated that treatment of cervicovaginal cell lines with ARV drugs can alter gene expression of drug transporters, suggesting that the mucosal disposition of ARV drugs delivered vaginally can be modulated by drug transporters.
This study aimed to investigate in vivo modulation of drug transporter expression in a non-human primate model by tenofovir and darunavir released from film formulations.
Cervicovaginal tissues were collected from drug-naïve macaques and from macaques vaginally treated with film formulations of tenofovir or darunavir. Drug release in vaginal fluid as well as drug absorption in cervicovaginal tissues and lymph nodes were verified by mass spectrometry. The effects of exposure to drugs on the expression of transporters relevant to ARV drugs were evaluated by quantitative PCR.
We showed expression in cervicovaginal tissue of drug-naïve macaques of transporters important for distribution of ARV drugs, albeit at lower levels compared to human tissue for key transporters including P-glycoprotein. Concentrations of tenofovir and darunavir well above the EC50 values determined in vitro were detected in vaginal fluid and vaginal tissues of macaques treated with drug-dissolving films over 24 hours and were also comparable to those shown previously to modulate drug transporter expression. Accordingly, Multidrug Resistance associated Protein 2 (MRP2) in cervicovaginal tissue was upregulated by both tenofovir and darunavir. The two drugs also differentially induced and/or inhibited expression of key uptake transporters for reverse transcriptase inhibitors and protease inhibitors.
The lower expression of key transporters in macaques may result in increased retention of ARV drugs at the simian cervicovaginal mucosa compared to the human mucosa and has implications for translation of pre-clinical data. Modulation of drug transporter expression by tenofovir and darunavir points to the potential benefit of MRP2 inhibition to increase ARV drug penetration through the cervicovaginal epithelium.
Original languageEnglish
Pages (from-to)852-864
Number of pages13
JournalMolecular Pharmaceutics
Volume17
Issue number3
Early online date4 Feb 2020
DOIs
Publication statusPublished - 2020

    Fingerprint

Keywords

  • Multidrug resistance associated protein
  • tenofovir
  • darunavir
  • microbicides
  • vagina
  • macaques
  • multidrug resistance associated protein
  • CELLS
  • PROTEASE INHIBITORS
  • P-GLYCOPROTEIN
  • VAGINAL RINGS
  • EFFLUX TRANSPORTERS
  • REVERSE-TRANSCRIPTASE INHIBITORS
  • DISOPROXIL FUMARATE
  • INTRACELLULAR ACCUMULATION
  • MULTIDRUG-RESISTANCE
  • EXPRESSION

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Hijazi, K., Iannelli, F., Cuppone, A. M., Desjardins, D., Caldwell, A., Dereuddre-Bosquet, N., Scala, C., Smith, K. A., Mukhopadya, I., Frank, B., Gwozdz, G., Santoro, F., Le Grand, R., Pozzi, G., & Kelly, C. G. (2020). In vivo modulation of cervicovaginal drug transporters and tissue distribution by film-released tenofovir and darunavir for topical prevention of HIV-1. Molecular Pharmaceutics, 17(3), 852-864. https://doi.org/10.1021/acs.molpharmaceut.9b01121